PARK CITY, Utah, Nov. 6, 2023 /PRNewswire/ -- BlueWind Medical, Ltd., a pioneer in the development and commercialization of a patient centric implantable Tibial NeuroModulation (iTNM) solution for ...
Axonics (NASDAQ:AXNX) said it acquired a lead placement solution from Radian which complements the company's existing sacral neuromodulation (SNM) offering. The company acquired the assets of Radian ...
“We believe the new Category I CPT codes will enable more predictable and consistent reimbursement for Barostim patients and healthcare professionals,” said Kevin Hykes, President and Chief Executive ...
The US Food and Drug Administration (FDA) has granted 510 (k) clearance for BlueWind Medical, Ltd.’s enhanced Revi® implantable tibial neuromodulator for treatment of urgency urinary incontinence (UUI ...
The growth of the neuromodulation market is driven majorly by the rising prevalence of neurological disorders, increasing research into expanding the applications of neuromodulation, and awareness on ...
We expect free cash flow to improve through the year as the pandemic-driven delays in neuromodulation procedures ease. Cash flow growth should accelerate as we head into 2023. The firm does not pay a ...
Boston Scientific’s BSX Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. This segment reflects the company’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback